Total Payments
$334,815
2024 Payments
$48,104
Companies
21
Transactions
317
Medicare Patients
850
Medicare Billing
$101,174
Payment Breakdown by Category
Other$200,000 (59.7%)
Consulting$101,967 (30.5%)
Travel$23,240 (6.9%)
Food & Beverage$9,471 (2.8%)
Research$117.14 (0.0%)
Education$20.23 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $196,400 | 63 | 58.7% |
| Consulting Fee | $101,967 | 26 | 30.5% |
| Travel and Lodging | $23,240 | 61 | 6.9% |
| Food and Beverage | $9,471 | 155 | 2.8% |
| Honoraria | $3,600 | 1 | 1.1% |
| Unspecified | $117.14 | 2 | 0.0% |
| Education | $20.23 | 9 | 0.0% |
Payments by Type
General
$334,698
315 transactions
Research
$117.14
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $90,199 | 103 | $0 (2024) |
| Daiichi Sankyo Inc. | $74,786 | 70 | $0 (2021) |
| Janssen Biotech, Inc. | $41,816 | 54 | $0 (2024) |
| PFIZER INC. | $39,162 | 8 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $35,271 | 30 | $0 (2017) |
| Eli Lilly and Company | $25,447 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $8,580 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,269 | 12 | $0 (2019) |
| Luitpold Pharmaceuticals Inc | $6,000 | 1 | $0 (2017) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,500 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,104 | 37 | Janssen Biotech, Inc. ($28,882) |
| 2023 | $25,117 | 13 | PFIZER INC. ($13,011) |
| 2022 | $19,440 | 19 | PFIZER INC. ($8,586) |
| 2021 | $8,411 | 4 | PFIZER INC. ($5,580) |
| 2020 | $17,428 | 8 | PFIZER INC. ($11,970) |
| 2019 | $77,998 | 78 | AbbVie, Inc. ($42,456) |
| 2018 | $29,735 | 42 | AbbVie, Inc. ($19,141) |
| 2017 | $108,581 | 116 | Daiichi Sankyo Inc. ($48,039) |
All Payment Transactions
317 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,737.50 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $119.59 | General |
| 12/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $7.95 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $31.61 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $138.28 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Eli Lilly and Company | OMVOH (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $9,382.50 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Eli Lilly and Company | OMVOH (Drug) | Food and Beverage | In-kind items and services | $33.48 | General |
| Category: Immunology | ||||||
| 09/23/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $89.56 | General |
| Category: HEMATOLOGY | ||||||
| 08/07/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $4,170.00 | General |
| Category: Immunology | ||||||
| 05/29/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| 05/29/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| 05/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,085.00 | General |
| Category: Immunology | ||||||
| 05/24/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Immunology | ||||||
| 05/24/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 05/19/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: Immunology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $146.28 | General |
| Category: Immunology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Immunology | ||||||
| 04/24/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $52.87 | General |
| Category: Immunology | ||||||
| 03/21/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $625.00 | General |
| 03/12/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $85.28 | General |
| Category: Immunology | ||||||
| 03/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $9,035.00 | General |
| Category: Immunology | ||||||
| 03/05/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $69.06 | General |
| Category: HEMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 259 | 291 | $252,663 | $31,543 |
| 2022 | 8 | 243 | 279 | $235,792 | $30,282 |
| 2021 | 8 | 254 | 293 | $204,614 | $29,401 |
| 2020 | 5 | 94 | 103 | $92,722 | $9,948 |
Total Patients
850
Total Services
966
Medicare Billing
$101,174
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 33 | 33 | $69,696 | $7,056 | 10.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 42 | 42 | $62,664 | $4,629 | 7.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 34 | $8,656 | $3,765 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 43 | $7,152 | $3,073 | 43.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 12 | 12 | $25,344 | $2,668 | 10.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 32 | 32 | $34,784 | $2,411 | 6.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 31 | $5,799 | $2,269 | 39.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $14,988 | $2,014 | 13.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 30 | $2,790 | $1,369 | 49.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $4,378 | $1,190 | 27.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 11 | 11 | $16,412 | $1,099 | 6.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 28 | 29 | $61,248 | $6,259 | 10.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 32 | $7,175 | $3,674 | 51.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 16 | 16 | $33,792 | $3,455 | 10.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 29 | 31 | $46,252 | $2,713 | 5.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 27 | 33 | $4,620 | $2,547 | 55.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 24 | 24 | $35,808 | $2,262 | 6.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 19 | 19 | $20,653 | $1,880 | 9.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Office | 2022 | 11 | 11 | $13,739 | $1,809 | 13.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 28 | $3,948 | $1,670 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 19 | $3,065 | $1,385 | 45.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 13 | $3,260 | $1,338 | 41.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 20 | 24 | $2,232 | $1,290 | 57.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 32 | 46 | $10,120 | $5,621 | 55.5% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 43 | 43 | $64,156 | $5,366 | 8.4% |
About Dr. Neilanjan Nandi, MD
Dr. Neilanjan Nandi, MD is a Gastroenterology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1710188974.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neilanjan Nandi, MD has received a total of $334,815 in payments from pharmaceutical and medical device companies, with $48,104 received in 2024. These payments were reported across 317 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($196,400).
As a Medicare-enrolled provider, Nandi has provided services to 850 Medicare beneficiaries, totaling 966 services with total Medicare billing of $101,174. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Philadelphia, PA
- Active Since 05/29/2007
- Last Updated 08/30/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1710188974
Products in Payments
- INJECTAFER (Drug) $75,622
- STELARA (Biological) $43,145
- TREMFYA (Drug) $28,769
- Entyvio (Biological) $8,226
- ZEPOSIA (Drug) $5,018
- Humira (Biological) $4,636
- OMVOH (Drug) $4,169
- VELSIPITY (Drug) $3,675
- XELJANZ (Drug) $3,636
- XIFAXAN (Drug) $2,500
- HUMIRA (Biological) $2,184
- SKYRIZI (Biological) $1,991
- Tremfya (Drug) $1,948
- MONOFERRIC (Drug) $158.62
- Sucraid (Drug) $133.62
- Mavyret (Drug) $124.85
- NATURABILAM W/INVISICTFPOKIT70MM (Device) $109.61
- ESD - Core Endoscopy (Device) $106.54
- Cimzia (Drug) $27.78
- XIFAXANIBSD (Drug) $23.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Philadelphia
Xiaoli Ma, Md, MD
Gastroenterology — Payments: $717,441
Gastroenterology $717,441
Gary Lichtenstein, Md, MD
Gastroenterology — Payments: $416,696
Gastroenterology $416,696
Dr. David Lichtenstein, M.d, M.D
Gastroenterology — Payments: $263,694
Gastroenterology $263,694
James Lewis, Md, MD
Gastroenterology — Payments: $229,188
Gastroenterology $229,188
Mark Osterman, Md, MD
Gastroenterology — Payments: $142,430
Gastroenterology $142,430
Dr. Oleg Volchonok, M.d, M.D
Gastroenterology — Payments: $116,291
Gastroenterology $116,291